Compare Aegon Ltd. (AEG) vs Johnson & Johnson (JNJ) Price & Performance

AEG trades at $9.415, down 0.37% on the day, with a bullish technical signal from moving averages. The company reported mixed recent earnings, beating expectations in Q2 and Q3 2025 but missing in Q4. Revenue for 2024 was $19.52 billion, with net income of $688 million. A dividend of $0.25 per share is scheduled for payment in July 2026. The balance sheet shows total assets of $327.39 billion and a declining debt-to-asset ratio, improving from 2.43 in 2020 to 1.46 in 2024.

AEG presents a moderate investment case with a low P/E of 13.54 and P/S of 0.57, suggesting potential undervaluation. Analyst sentiment is mixed with a 27.78% buy rating. Key risks include volatile cash flows and execution of strategic shifts, such as the relocation to the U.S. and partnership developments. The stock's outlook hinges on sustained profitability and successful implementation of corporate simplifications.

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.